In summary, the inhibition of saturated fatty acid absorption from the small intestine by PHGG may not only prevent sarcopenia by improving insulin resistance in skeletal muscle and suppressing the expression of muscle atrophy-related genes but also prevent various metabolic disorders by suppressing accumulation in visceral fat and improving encephalopathy in visceral fat. Here, INS is linked to metabolic disease.